GYRE

Gyre Therapeutics (GYRE)

About Gyre Therapeutics (GYRE)

Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The firm operates through the BC and Gyre segments. The company was founded on March 7, 1997 and is headquartered in San Diego, CA.

Details

Daily high

$7.35

Daily low

$6.92

Price at open

$7.30

52 Week High

$14.42

52 Week Low

$6.11

Market cap

648.0M

Dividend yield

0.00%

Volume

462,049

Avg. volume

88,739

P/E ratio

187.14

Gyre Therapeutics News